Skip to main content
Premium Trial:

Request an Annual Quote

GMSbiotech, PTS Partner to Develop Array-based Antibody Screening Solution

NEW YORK (GenomeWeb News) – GMSbiotech and Pure Transplant Solutions today announced a partnership to develop a new antibody screening solution.

The partnership leverages GMSbiotech's microarray-based diagnostic platform for personalized medicine and transplantation compatibility and PTS' HLA reagents, which include more than 200 Class I and II alleles. That number is anticipated to grow to more than 300 alleles during the course of the deal announced today, GMSbiotech and PTS said.

PTS CEO Thomas Harlan said that his firm has invested more than $15 million in the last 14 years to develop its PTS reagent technology, while GMSbiotech has invested more than $10 million during the past decade developing its platform.

"Leveraging our combined infrastructures and unique strengths will allow us to develop a novel technology solution while lowering the risk, time, and costs normally associated with these types of ventures," Harlan said in a statement.

Inverness, Ill.-based GMSbiotech develops genetic and serology tests based on its raw sample genotyping technology in combination with its microarray platform.

PTS is a subsidiary of Pure Protein based in Oklahoma City, Okla., and develops HLA protein technology methods and immunology tools for diagnostic and therapeutic applications.

Financial and other terms of the deal were not disclosed.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.